Classical neurotransmitters and neuropeptides involved in major depression in a multi-neurotransmitter system: A focus on antidepressant drugs

Current Medicinal Chemistry

Volumn 20, Issue 38, 2013, Pages 4853-4858

  Werner, Felix Martin ^a,b   Covenas R ^b  

^a Höhere Berufsfachschule Für Altenpflege ^*  (Germany)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Corticotropin releasing hormone; Dopamine; GABA; Glutamate; Neuropeptide Y; Noradrenaline; Serotonin; Substance P

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; AMFEBUTAMONE; AMITIFADINE; ANTIDEPRESSANT AGENT; APREPITANT; BUSPIRONE; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; DOPAMINE; DULOXETINE; ESCITALOPRAM; GALANIN; GLUTAMINE; HYDROCORTISONE; MESSENGER RNA; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; PAROXETINE; PROTIRELIN; SEROTONIN; SEROTONIN RECEPTOR; SUBSTANCE P; UNINDEXED DRUG; VILAZODONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NEUROPEPTIDE; NEUROTRANSMITTER UPTAKE INHIBITOR;

ARTICLE; BRAIN STEM; DIARRHEA; DNA POLYMORPHISM; GABAERGIC SYSTEM; GENE ACTIVATION; HEALTH CARE COST; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; MAJOR DEPRESSION; MULTICENTER STUDY (TOPIC); NAUSEA; NERVE CELL NETWORK; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PRESYNAPTIC INHIBITION; REMISSION; SIDE EFFECT; CHEMISTRY; DEPRESSION; METABOLISM; PATHOLOGY;

ANTIDEPRESSIVE AGENTS; DEPRESSION; GABAERGIC NEURONS; HIPPOCAMPUS; HUMANS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; NEUROTRANSMITTER UPTAKE INHIBITORS; RECEPTORS, GABA;

EID: 84889561442     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660280     Document Type: Article

References (32)

1. Godin, O.; Dufouil, C.; Ritchie, K.; Dartigues, J.F.; Taourio, C.; Peres, K.; Artero, S.; Alpérovitch, A. Depressive symptoms, major depressive episode and cognition in the elderly: the three-city study. Neuroepidemiology, 2007, 28(2), 101-108. (Pubitemid 46633199)
2. Czira, M.E.; Wersching, H.; Baune, B.T.; Berger, K. Brain-derived neurotrophic factor gene polymorphisms, neurotransmitter levels, and depressive symptoms in an elderly population. Age(Dordr.), 2012, 34(6), 1529-1541.
3. Hollander, A.C.; Bruce, D.; Ekberg, J.; Burström, B.; Ekblad, S. Hospitalisation for depressive disorder following unemploymentdifferentials by gender and immigrant status: a population-based cohort study in Sweden. J. Epidemiol. Community Health, doi: 10.1136/jech-2013-202701(Jul 18, 2013).
4. Frieling, H.; Hillemacher, T.; Demling, J.H.; Kornhuber, J.; Bleich, S. New options in the treatment of depression. Fortschr. Neurol. Psychiatr., 2007, 75(11), 641-652. (Pubitemid 350205647)
5. Werner, F.-M.; Coveñas, R. Classical neurotransmitters and neuropeptides involved in major depression: a review. Int. J. Neurosci., 2010, 120(7), 455-470.
6. de Silva, V.A.; Hanwella, R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies. Int. Clin. Psychopharmacol., 2011, 27(1), 8-16.
7. Gendall, K.A.; Joyce, P.R.; Mulder, R.L.; Luty, S.E. Thyroid indices and response to fluoxetine and nortriptyline in major depression. J. Psychopharmacol., 2003, 17(4), 431-437. (Pubitemid 38076339)
8. Cervilla, J.A.; Molina, E.; Rivera, M.; Torres-González, F.; Bellón, J.A.; Moreno, B. Luna, J.D.; Lorente, J.A.; Mayoral, F.; King, M.; Nazareth, I.; PREDICT study Core group; Gutiérrez, B. The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5-HTTLPR genotype: evidence from the Spanish PREDICT Gen cohort. Mol. Psychiatry, 2007, 12(8), 748-755. (Pubitemid 47172690)
9. Werner, F.-M.; Coveñas, R. The different brain centres involved in major depression and the derived pharmacological options. Klin. Neurol., 2011, 42, 61.
10. Bonaventure, P.; Kelly, L.; Aluisio, L.; Shelton, J.; Lord, B.; Galici, R.; Miller, K.; Attack, J.; Lovenberg, T.W.; Dugovic, C. Selective blockade of 5HT7 receptors enhances 5-HT neurotransmission, antidepressant-like behavior and REM sleep suppression induced by citalopram in rodents. J. Pharmacol. Exp. Ther., 2007, 32(2), 690-698. (Pubitemid 46624521)
11. Owen, R.T. Vilzodone: a new treatment option for major depressive disorder. Drugs Today(Barc.), 2011, 47(7), 531-537.
12. Nutt, D.J.; Demyttenaere, K.; Janka, Z.; Aarre, T., Bourin, M.; Canonico, P.L: Carrasco, J.L.; Stahl, S. The other face of depression, reduced positive effect: the role of catecholamines in causation and cure. J. Psychopharmacol., 2007, 21(5), 461-471. (Pubitemid 47106935)
13. Vlahiotis, A.; Devine, S.T.; Eichholz, J.; Kautzner, A. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI and SNRI antidepressants in commercial health plans. J. Manag. Care Pharm., 2011, 17(2), 123-132.
14. Signorovitch, J.; Ramakrishnan, K.; Ben-Hamadi, R.; Yu, A.P.; Wu, E.Q.; Dworak, H.; Erder, M.H. Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Curr. Med. Res. Opin., 2011, 27(6), 1089-1096.
15. Sennfelt, D.A.; Marques da Silva, M.A.; Tavares, A.P. Bupropion in the treatment of major depressive disorder in real-life practice. Clin. Drug Investig., 2011, 31(1), 19-24.
16. Kornum, B.R.; Weikop, P.; Moller, A.; Ronn, L.C.; Knudsen, G.; Aznar, S. Serotonin depletion reuptake in a decrease of the neuronal activation by rivastigmine in the rat hippocampus. Brain Res., 2006, 262(8), 1073-1074.
17. McGranahan, T.M.; Patzlaff, N.E.; Grady, S.R.; Heinemann, S.E.; Booker, T.K. Alpha4beta2 nicotinic acetylcholine receptors on dopaminergic neuron mediate nicotine reward and anxiety relief. J. Neurosci., 2011, 31(30), 10891-10902.
18. Nowak, G.; Partyka, A.; Palucha, A.; Szawczyk, B.; Wieronska, J.M.; Dybata, M. Metz, M.; Librowski, T.; Froestl, W.; Papp, M.; Pilc, A. Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br. J. Pharmacol., 2006, 149(5), 581-590. (Pubitemid 44658519)
19. Ghose, S.; Winter, M.K.; McCanson, K.E.; Tammings, C.A.; Enna, S.J. The GABAβ receptor as a target for antidepressant drug action. Br. J. Pharmacol., 2011, 162(1), 1- 17.
20. Sanacora, G.; Kendell, S.F.; Levin, Y.; Simon, A.A.; Tenton, L.R.; Covic, V.; Krystal, J.H. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol. Psychiatry, 2007, 61(6), 822-825. (Pubitemid 46330247)
21. Palucha, A. Are compounds acting at metabotropic glutamate receptors the answer to treating depression? Expert Opin. Investig. Drugs, 2006, 15(12), 1545-1553. (Pubitemid 44848978)
22. Pomiemy-Chamiolo, L.; Poleszak, E.; Pilc, A.; Nowak, G. NMDA but not AMPA glutaminergic receptors are involved in the antidepressant- like activity of MTEP during the forced swim test in mice. Pharmacol. Rep., 2010, 62(6), 1186-1190.
23. Werner, F.-M.; Coveñas, R. In: Focus on Neuropeptide Research; Coveñas, Mangas and Narváez, Eds.; Transworld Research Network: Trivandrum, 2007; pp. 299-339.
24. Werner, F.-M.; Coveñas, R. Classical neurotransmitters and neuropeptides involved in generalized epilepsy; a focus on antiepileptic drugs. Curr. Med. Chem., 2011, 18(32), 4933-4948.
25. Werner, F.-M.; Coveñas, R. Neuropeptides involved in schizophrenia. Curr. Top. Neurochem., 2005, 4, 35-49.
26. Nikisch, G.; Agren, H.; Eap, C.B.; Czernik, A.; Baumann, P.; Mathe, A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol., 2005, 8(3), 403-416.
27. Chen, C.; Wilcoxen, K.M.; Huang, C.Q.; Xie, Y.F.; McCarthy, J.R.; Webb, T.R.; Zhu, Y.F.; Saunders, J.; Liu, X.J.; Chen, T.K.; Bozigian, H.; Grigoriadis, D.E. Design of 2,5-methyl-3-(6- dimethyl-4-methylpyridin-3-yl)-7- dipropylaminopyrazol1,5-apyrimidine (NBI 30775/R121919) and structure - activity relationships of a series of potent and orally active corticotropin releasing factor receptor antagonists. J. Med. Chem., 2004, 47(19), 4787-4798. (Pubitemid 39195568)
28. Isogawa, K.; Nagayama, H.; Tsutsumi, T.; Kiyota, A.; Akiyoshi, J.; Hieda, K. Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropin-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder. J. Psychiatr. Res., 2005, 39(5), 467-473. (Pubitemid 40909990)
29. Keller, M.; Montgomery, S.; Ball, W.; Morrison, M.; Snavely, D.; Liu, G.; Hargreaves, R.; Hietala, J.; Lines, C.; Beebe, K.; Reines, S. Lack of efficacy of the substance P(neurokinin-1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry, 2006, 59(3), 216-233.
30. Lu, X.; Barr, A.M.; Kinney, J.W.; Sanna, P.; Conti, B.; Behrens, M.M.; Bartfai, T. A role for galanin in antidepressant action with a focus in the dorsal raphe nucleus. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(3), 874-879. (Pubitemid 40282758)
31. Navines, R.; Martín-Santos, R.; Gómez-Gil, B.; Martínez de Osaba, M.J.; Imaz, M.L.; Gasto, L. Effects of citalopram treatment on hypothermic and hormal responses to the 5-HT(1A) receptor agonist buspirone in patients with major depression and therapeutic response. Psychoendocrinology, 2007, 32(3), 307-312.
32. Tran, P.; Skolnick, P.; Czobor, P.; Huang, N.Y.; Bradshaw, M.; McKinney, A.; Fava, M. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebocontrolled study. J. Psychiatr. Res., 2011, 46(1), 64-71.